Plasma Rich in Growth Factors in Corneal Endothelial Transplantation
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorUniversity of Miami
About this trial
The purpose of the study is to determine the safety and efficacy of brief intraoperative corneal endothelial graft incubation in plasma rich in growth factors (PRGF) for reducing postoperative endothelial cell loss.
Eligibility criteria
Qualifiers
undergoing endothelial keratoplasty (DSEK or DMEK) at the Bascom Palmer Eye Institute or Price Vision Group, using corneal graft tissue within 14 days of preservation
Disqualifiers
History of corneal transplantation in the study eye, Best corrected visual acuity (BCVA) worse than 20/40 in the contralateral eye, systemic immunosuppression, previous intraocular surgical procedures (other than cataract surgery) such as glaucoma tubes or silicone oil.
Adults unable to consent
Pregnant women
Prisoners
Trial design
Treatments tested in this trial
- Endothelial keratoplasty
- PRGF
Treatment groups
100 Participants
are divided into 2 treatment groupsSponsors and collaborators
University of Miami
Lead sponsor
Beauty of Sight
Collaborator
Source ClinicalTrials.gov